Kinnate Biopharma Stock Working Capital
Kinnate Biopharma fundamentals help investors to digest information that contributes to Kinnate Biopharma's financial success or failures. It also enables traders to predict the movement of Kinnate Stock. The fundamental analysis module provides a way to measure Kinnate Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kinnate Biopharma stock.
Kinnate |
Kinnate Biopharma Company Working Capital Analysis
Kinnate Biopharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Kinnate Biopharma Working Capital | 146.18 M |
Most of Kinnate Biopharma's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kinnate Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionBased on the company's disclosures, Kinnate Biopharma has a Working Capital of 146.18 M. This is 65.66% lower than that of the Biotechnology sector and 72.86% lower than that of the Health Care industry. The working capital for all United States stocks is 90.11% higher than that of the company.
Kinnate Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kinnate Biopharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics of similar companies.Kinnate Biopharma is currently under evaluation in working capital category among its peers.
Kinnate Fundamentals
| Return On Equity | -0.56 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (25.71 M) | |||
| Shares Outstanding | 47.17 M | |||
| Shares Owned By Insiders | 0.15 % | |||
| Shares Owned By Institutions | 82.58 % | |||
| Number Of Shares Shorted | 465.63 K | |||
| Price To Book | 0.79 X | |||
| EBITDA | (118.21 M) | |||
| Net Income | (112.65 M) | |||
| Cash And Equivalents | 262.42 M | |||
| Cash Per Share | 5.94 X | |||
| Total Debt | 3.17 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 23.30 X | |||
| Book Value Per Share | 3.66 X | |||
| Cash Flow From Operations | (100.04 M) | |||
| Short Ratio | 0.96 X | |||
| Earnings Per Share | (2.78) X | |||
| Target Price | 2.36 | |||
| Number Of Employees | 84 | |||
| Beta | 1.34 | |||
| Market Capitalization | 124.99 M | |||
| Total Asset | 173.6 M | |||
| Retained Earnings | (372.01 M) | |||
| Working Capital | 146.18 M | |||
| Z Score | 19.38 | |||
| Net Asset | 173.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |